Article
Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Frontiers in immunology - 1 Jan 2023
Zelba Henning, Rabsteyn Armin, Bartsch Oliver, Kyzirakos Christina, Kayser Simone, Seibold Marcel, Harter Johannes, Latzer Pauline, Hadaschik Dirk, Battke Florian, Golf Alexander, Rettig Matthew B, Biskup Saskia
Abstract excerpt
Localized prostate cancer is curable, but metastatic castration sensitive prostate cancer has a low 5-year survival rate, while broad treatment options are lacking. Here we present an mCSPC patient under remission receiving individualized neoantigen-derived peptide vaccination as recurrence prophylaxis in the setting of an individual treatment attempt. The patient was initially analyzed for somatic tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.